SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ADAG

Adagene Inc. (NASDAQ:ADAG)

CN · Delayed Price · Currency is USD
Healthcare · Biotechnology
$1.76-$0.25 (-12.44%)
 
Market cap
$66.3M
Insider Score
Health Score
Analyst consensus
Listed since
Feb 9, 2021
Market Cap$66.26M-2.2%
Revenue (ttm)$9.32M+1054.7%
Net Income-$20.56M-85.2%
EPS-$0.47-71.1%
Shares Out37.65M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,371,420
Open$2.00
Previous Close$2.01
Day's Range$1.35 - $2.05
52-Week Range$1.27 - $4.85
Beta0.54
AnalystsBuy
Price Target$8.25(+368.75%)
Earnings DateMar 31, 2027

About ADAG

Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.

Address
Building C14, Suzhou, JS, 215123, CN
Market Cap
66 million
Employees
128
Industrial Classification
Biotechnology

Adagene Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
45th Percentile Overall Score
ADAG InsiderScore:66 / 99

Adagene Inc. scored higher than 45% of companies evaluated by InsiderBuying, and ranked 46th out of 107 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Adagene Inc. bought $70.0K of stock across 2 purchases in the last 90 days, the largest of them $64.0K.

Stake Increase

The average purchase added about 24% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$162.24K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
2 Buy0 Hold0 SellAvg target $10.00 (+397.5%)

2 firms rating ADAG in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From ADAG’s reported statements · Q2 2026 (trailing 12 months)

Next catalysts

1 Day
-12.44%
5 Days
+3.53%
1 Month
-26.97%
6 Months
-53.56%
1 Year
-2.22%

$ADAG stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ADAG holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ADAG's directors and management

Net Shares Purchased by Insiders−50k−25k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ADAG Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New ADAG patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ADAG from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ADAG

PGJInvesco Golden Dragon China ETF$103.26K
EWXState Street SPDR S&P Emerging Markets Small Cap ETF$55.07K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ADAG’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
75.94
Analyst Ratings
32% of score
60
News & Sentiment
20% of score
72

News check: Multiple positive clinical milestones including Phase 1 dosing initiation, Phase 2 enrollment completion, and new trial launch demonstrate pipeline progress and advancement.

Recent Insider Activity

Buys
5
Sells
0
Buy Value
$162.24K
Distinct Buyers
3

Insider Score Trend Over Time

-13.2 since Sep 24
0255075100Sep 24 — Insider Score 78.3Sep 25 — Insider Score 87.1Sep 26 — Insider Score 93.1Sep 27 — Insider Score 93.1Sep 28 — Insider Score 93.0Sep 29 — Insider Score 92.8Sep 30 — Insider Score 92.5Oct 1 — Insider Score 92.5Oct 2 — Insider Score 55.0Oct 3 — Insider Score 92.1Oct 4 — Insider Score 92.0Oct 5 — Insider Score 92.1Oct 6 — Insider Score 91.8Oct 7 — Insider Score 91.5Oct 8 — Insider Score 91.4Oct 9 — Insider Score 91.2Oct 10 — Insider Score 91.1Oct 11 — Insider Score 91.4Oct 12 — Insider Score 91.5Oct 13 — Insider Score 91.2Oct 14 — Insider Score 91.0Oct 15 — Insider Score 91.0Oct 16 — Insider Score 90.8Oct 17 — Insider Score 90.6Oct 18 — Insider Score 90.8Oct 19 — Insider Score 90.6Oct 20 — Insider Score 90.7Oct 21 — Insider Score 90.5Oct 22 — Insider Score 90.5Oct 23 — Insider Score 90.4Oct 24 — Insider Score 90.3Oct 25 — Insider Score 90.2Oct 26 — Insider Score 90.2Oct 27 — Insider Score 90.1Oct 28 — Insider Score 90.1Oct 29 — Insider Score 89.9Oct 30 — Insider Score 89.2Oct 31 — Insider Score 89.1Nov 1 — Insider Score 89.1Nov 2 — Insider Score 87.4Nov 3 — Insider Score 85.5Nov 4 — Insider Score 85.0Nov 5 — Insider Score 84.2Nov 6 — Insider Score 83.4Nov 7 — Insider Score 83.0Nov 8 — Insider Score 83.4Nov 9 — Insider Score 83.5Nov 10 — Insider Score 82.4Nov 11 — Insider Score 81.5Nov 12 — Insider Score 74.4Nov 13 — Insider Score 73.1Nov 14 — Insider Score 71.9Nov 15 — Insider Score 72.3Nov 16 — Insider Score 71.7Nov 17 — Insider Score 70.1Nov 18 — Insider Score 68.6Nov 19 — Insider Score 67.3Nov 20 — Insider Score 65.6Nov 21 — Insider Score 64.8Nov 22 — Insider Score 65.1Sep 24Oct 23Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

PGJInvesco Golden Dragon China ETF0.14%

Weight is the stock’s share of each fund’s holdings.